Edward M. Wolin, MD, Named Director of Center for Carcinoid and Neuroendocrine Tumors at Mount Sinai
Edward M. Wolin, MD
EDWARD M. WOLIN, MD, an internationally renowned authority on neuroendocrine tumors, has joined the Mount Sinai Health System as Director of the Center for Carcinoid and Neuroendocrine Tumors. This multidisciplinary center includes specialists in gastroenterology, surgical oncology, hepatobiliary surgery, thoracic surgery, nuclear medicine, cardiology, medical oncology, radiology, pathology, endocrinology, and nutrition.
Dr. Wolin, who will also be Professor of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, brings to Mount Sinai a robust research program; it includes clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis.
Dr. Wolin will lead the multidisciplinary center along with Michelle Kang Kim, MD, PhD, Associate Professor of Gastroenterology. Dr. Kim will also serve as Associate Director after previously serving as Interim Director.
DR. WOLIN was most recently Director of the Neuroendocrine Tumor Program at the Montefiore Einstein Center for Cancer Care. He has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, antiangiogenic drugs, and peptide receptor radiotherapy. In addition, he was previously Director of Neuroendocrine Tumor Programs at the University of Kentucky Medical Center and Cedars-Sinai Medical Center in Los Angeles. ■